Evaluation of androgen receptor and androgen receptor splice-variant 7 in bladder cancer; a novel approach into an ancient topic.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
31 Jul 2024
Historique:
received: 23 01 2024
accepted: 08 07 2024
medline: 31 7 2024
pubmed: 31 7 2024
entrez: 31 7 2024
Statut: epublish

Résumé

The contribution of androgen receptors (AR) on bladder cancer has been demonstrated in pre-clinical studies, however in clinical studies, only the canonical AR (AR-FL) protein was measured by immunohistochemistry and conflicting results were obtained. To get better insight into the alterations of AR signalling, we used western blotting (WB) method and simultaneously measured both mRNA and protein levels of AR-FL and AR-V7. 23 naive non-muscle invasive bladder cancer patients and 12 healthy individuals were included. AR-FL protein, AR-FL mRNA, AR-V7 protein and AR-V7 mRNA levels were quantitatively measured by WB and qRT-PCR. While AR-FL protein and AR-V7 mRNA were significantly higher in bladder cancer, AR-FL mRNA and AR-V7 protein were lower. AR-V7 mRNA level was higher in patients with tumour size over 3 cm and AR-FL protein was higher in single tumours (p < 0,005). The small sampling size and the inclusion of only male participants were the main limitations. The increase of AR-FL protein in bladder cancer supports the contribution of the AR pathway in bladder cancer. The presence of high AR-FL protein despite low mRNA levels may be due to a disruption in post-transcriptional regulatory mechanisms. AR-V7 was demonstrated for the first time in bladder tissue and found significantly different in bladder cancer tissues. Our study reached new and valuable findings and will shed light on the studies that aim to clarify the role of the AR pathway in bladder cancer.

Identifiants

pubmed: 39083104
doi: 10.1007/s00345-024-05166-z
pii: 10.1007/s00345-024-05166-z
doi:

Substances chimiques

Receptors, Androgen 0
AR protein, human 0
RNA, Messenger 0
Protein Isoforms 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

459

Informations de copyright

© 2024. The Author(s).

Références

Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K et al (2012) Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 109(11):1716–1726
doi: 10.1111/j.1464-410X.2011.10706.x pubmed: 22221549
Li D, Zhou W, Pang J, Tang Q, Zhong B, Shen C et al (2019) A magic drug target: androgen receptor. Med Res Rev 39(5):1485–1514
doi: 10.1002/med.21558 pubmed: 30569509
Wach S, Taubert H, Cronauer M (2020) Role of androgen receptor splice variants, their clinical relevance and treatment options. World J Urol [Internet]. 38(3):647–56. https://doi.org/10.1007/s00345-018-02619-0
Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y et al Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst [Internet]. 2007 Apr 4 [cited 2022 Jan 12];99(7):558–68. https://pubmed.ncbi.nlm.nih.gov/17406000/
Eric C, Kauffman BD, Robinson M, Downes LG, Powell MM, Lee DS, Scherr, Lorraine J, Gudas (2011) and NPM. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog 2011 December; 50(12):931–944. https://doi.org/101002/mc2075
Mir C, Shariat SF, Van Der Kwast TH, Ashfaq R, Lotan Y, Evans A et al (2011) Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int 108(1):24–30
doi: 10.1111/j.1464-410X.2010.09834.x pubmed: 21070579
Sanguedolce F, Cormio L, Carrieri G, Calò B, Russo D, Menin A et al (2020) Role of androgen receptor expression in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Histol Histopathol 35(5):423–432
pubmed: 31803932
Tuygun C, Kankaya D, Imamoglu A, Sertcelik A, Zengin K, Oktay M et al (2011) Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: A comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol Semin Orig Investig [Internet]. 29(1):43–51. https://doi.org/10.1016/j.urolonc.2009.01.033
Laor E, Schiffman ZJ, Braunstein JD, Reid RE, Tolia BM, Koss LG et al (1985) Androgen receptors in bladder tumors. Urology 25(2):161–163
doi: 10.1016/0090-4295(85)90534-5 pubmed: 2578695
Mashhadi R, Pourmand G, Kosari F, Mehrsai A, Salem S, Pourmand MR et al (2014) Role of steroid hormone receptors in formation and progression of bladder carcinoma: a case-control study. Urol J 11(6):1968–1973
pubmed: 25433476
Yonekura S, Terauchi F, Hoshi K, Yamaguchi T, Kawai S (2019) Androgen receptor predicts first and multiple recurrences in Non-muscle Invasive Urothelial Carcinoma of the bladder. Pathol Oncol Res 25(3):987–994
doi: 10.1007/s12253-018-0431-7 pubmed: 29862474
Tripathi A, Gupta S (2020) Androgen receptor in bladder cancer: A promising therapeutic target. Asian J Urol [Internet]. 7(3):284–90. https://doi.org/10.1016/j.ajur.2020.05.011
Gwozdz T, Dorey K (2017) Western blot. Basic Sci Methods Clin Res. ;99–117
Najafov A, Hoxhaj G Western Blot Guru [Internet]. Western Blotting Guru. 2017 [cited 2023 Dec 10]. 5–19 p. http://www.sciencedirect.com:5070/book/9780128135372/western-blotting-guru
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC et al AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med [Internet]. 2014 Sep 11 [cited 2022 Feb 5];371(11):1028–38. https://pubmed.ncbi.nlm.nih.gov/25184630/
Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H et al (2009) A novel androgen receptor splice variant is upregulated during prostate Cancer progression and promotes androgen-depletionresistant growth. Cancer Res 69(6):2305–2313
doi: 10.1158/0008-5472.CAN-08-3795 pubmed: 19244107 pmcid: 2672822
Bozkaya G, Korhan P, Çokakli M, Erdal E, Saǧol Ö, Karademir S et al (2012) Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer 11:1–16
doi: 10.1186/1476-4598-11-64
Dauki AM, Blachly JS, Kautto EA, Ezzat S, Abdel-Rahman MH, Coss CC Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression. Cancer Res [Internet]. 2020 Feb 1 [cited 2022 Jan 8];80(3):561–75. https://pubmed.ncbi.nlm.nih.gov/31685543/
Uo T, Plymate SR, Sprenger CC (2018) The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets [Internet]. ;22(3):201–16. https://doi.org/10.1080/14728222.2018.1439016
Boorjian S, Ugras S, Mongan NP, Gudas LJ, You X, Tickoo SK et al (2004) Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 64(2):383–388
doi: 10.1016/j.urology.2004.03.025 pubmed: 15302512
Ma T, Bai S, Qi Y, Zhan Y, Ungerleider N, Zhang DY et al (2021) Increased transcription and high translation efficiency lead to accumulation of androgen receptor splice variant after androgen deprivation therapy. Undefined 504:37–48
Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z et al (2011) Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1. Cancer Cell [Internet]. 20(4):457–71. https://doi.org/10.1016/j.ccr.2011.09.001
Katleba K, Lombard AP, Tsamouri MM, Baek HB, Nishida KS, Libertini SJ et al (2021) Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis. Cancer Lett [Internet]. Apr 28 [cited 2022 Jan 8];504:49–57. https://pubmed.ncbi.nlm.nih.gov/33549708/
Roggero CM, Jin L, Cao S, Sonavane R, Kopplin NG, Ta HQ et al A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells. Oncogene 2020 406 [Internet]. 2020 Dec 15 [cited 2022 Jan 8];40(6):1106–17. https://www.nature.com/articles/s41388-020-01585-5

Auteurs

Ege Alper Sarıkaya (EA)

Dokuz Eylul University Hospital Urology Department, Edirne, Turkey. ege.sarikaya@deu.edu.tr.

Peyda Korhan (P)

Izmir Biomedicine and Genome Center, Balcova, Izmir, 35340, Turkey.
Galen Research Center, Izmir Tinaztepe University, Buca, Izmir, 35400, Turkey.
Department of Medical Biology and Genetics, Faculty of Medicine, Izmir Tinaztepe University, Buca, Izmir, 35400, Turkey.

Canet Incir (C)

Dokuz Eylul University Hospital Medical Pharmacology Department, İzmir, Turkey.

Alperen H Yıldız (AH)

Bolu Abant Izzet Baysal Üniversitesi Faculty of Medicine University Hospital Urology Department, Bolu, Turkey.

Dogan M Deger (DM)

Edirne Sultan 1. Murat State Hospital, Edirne, Turkey.

Selçuk M Özer (SM)

Dokuz Eylul University Hospital Urology Department, Edirne, Turkey.

Yesim Tuncok (Y)

Dokuz Eylul University Hospital Medical Pharmacology Department, İzmir, Turkey.

Gul Ergor (G)

Dokuz Eylul University Hospital Public Health Department, Izmir, Turkey.

Yasemin Ö Islakoğlu (YÖ)

Izmir Biomedicine and Genome Center, Balcova, Izmir, 35340, Turkey.

Volkan Sen (V)

Dokuz Eylul University Hospital Urology Department, Edirne, Turkey.

Ozan Bozkurt (O)

Dokuz Eylul University Hospital Urology Department, Edirne, Turkey.

Neşe Atabey (N)

Izmir Biomedicine and Genome Center, Balcova, Izmir, 35340, Turkey.
Galen Research Center, Izmir Tinaztepe University, Buca, Izmir, 35400, Turkey.
Department of Medical Biology and Genetics, Faculty of Medicine, Izmir Tinaztepe University, Buca, Izmir, 35400, Turkey.

Adil A Esen (AA)

Dokuz Eylul University Hospital Urology Department, Edirne, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH